Page 29 - The Indian EYE 010821
P. 29

Business EYE                                                            JANUARY 08, 2021  |       The Indian Eye                          29





























































                                                              BUSINESS  BRIEFS



               Reliance capital’s                                         Biocon Biologics gets Rs 555


                debt swells to Rs                                      crore capital injection from aDQ



                    20,380 crore

                                                                               bu Dhabi-based ADQ will  globe,” she said in a statement on
                                                                               invest  Rs  555  crore  for  1.8  Thursday.
                 nil Ambani-led Reliance Capital has said its to- Aper cent minority stake in                       Christiane Hamacher, CEO and
                 tal outstanding debt rose to nearly Rs 20,380        Biocon Biologics, valuing it at a post  Managing Director of Biocon Bio-
        Acrore  by  end-December  2020.  In  September                money valuation of 4.17 billion dol-       logics, said the ADQ equity funding
        last  year,  it  had  reported  a  total  debt  of  Rs  19,806   lars (about Rs 30,482 crore). Post the  in Biocon Biologics endorses the
        crore. Now, the principal amount due to HDFC Ltd              completion of transaction, Biocon  value of company’s business model
        is Rs 523.98 crore and to Axis Bank Rs 100.63 crore,          Ltd  will  hold  89.89  per  cent  stake  and strengthens its resolve to be the
        Reliance Capital said in regulatory filings at stock ex-      in Biocon Biologics on a fully dilut-      global leader in biologics, delivering
        changes.                                                      ed basis. “This investment is an en-       affordable access to innovative and
            “The total amount of outstanding borrowings from          dorsement of the value that Biocon  inclusive healthcare solutions, trans-
        banks and financial institutions works out to Rs 700.76       Biologics business has built as a ful-     forming patients’ lives.
        crore, including accrued interest up to December 31,”         ly  integrated  pure-play  biosimilars        Mohamed Hassan Alsuwaidi,
        it said. “Total financial indebtedness of the listed entity,   company and will enable us to ex-         Chief  Executive  Officer  of  ADQ,
        including short-term and long-term debt and accrued           pand our capabilities further,” said  said: “Our long-term ambition for
        interest, was Rs 20,379.71 crore at the end of Decem-         Kiran Mazumdar-Shaw, Executive  ADQ’s healthcare and pharma port-
        ber 2020.” The company said delay in debt servicing is        Chairperson of Biocon.                     folio is to create a provision-centred,
        due to prohibition to dispose off, alienate, encumber             “We welcome ADQ as our in-             digitally enhanced ecosystem that is
        either directly or indirectly or otherwise part with the      vestment partner as we pursue our  anchored in world-class clinical ex-
        possession of any assets by the Delhi High Court, the         shared goal of expanding access to  cellence, effective population health
        Debts Recovery Tribunal in Mumbai and the Bombay              high-quality,  affordable  biophar-        management and resilient supply
        High Court.                                                   maceuticals to patients across the  chain infrastructure.”


                                                               www.TheIndianEYE .us
   24   25   26   27   28   29   30   31   32   33   34